Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases.

Trends in cardiovascular medicine - 1 May 2024

Luo Fei, Das Avash, Khetarpal Sumeet A, Fang Zhenfei, Zelniker Thomas A, Rosenson Robert S, Qamar Arman

Abstract excerpt

Optimal management of low-density lipoprotein cholesterol (LDL-C) is a central tenet in the primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD). However, significant residual cardiovascular risk remains despite achieving guideline-directed LDL-C levels, in part due to mixed hyperlipidemia with elevated fasting and non-fasting triglyceride-rich lipoprotein levels. Advances in human...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiopoietin-Like Protein 3
Share to Cholesterol, LDL

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Dyslipidemias

Share to Gene Editing

Share to Heart Disease Risk Factors

Share to Hypolipidemic Agents

Share to Molecular Targeted Therapy

Share to Oligonucleotides, Antisense

Source

Identifiers

PMID: 36746257
DOI: 10.1016/j.tcm.2023.01.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases.PMID 36746257Read ↗

New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.Semantic proximity Read ↗

Familial combined hypolipidemia: angiopoietin-like protein-3 deficiencySemantic proximity Read ↗

ANGPLT3 in cardio-metabolic disorders.Semantic proximity Read ↗

ANGPTL3 Deficiency and Protection Against Coronary Artery DiseaseSemantic proximity Read ↗

Angiopoietin-like 3 in lipoprotein metabolism.Semantic proximity Read ↗

Addressing dyslipidemic risk beyond LDL-cholesterol.Semantic proximity Read ↗

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.Semantic proximity Read ↗

How ANGPTL3 Inhibition Will Help Our Clinical Practice?Semantic proximity Read ↗

Impacts of angiopoietin-like proteins on lipoprotein metabolism and cardiovascular events.Semantic proximity Read ↗

Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic riskSemantic proximity Read ↗

Genetic inhibition of angiopoietin-like protein-3, lipoprotein-lipid levels and cardiometabolic diseasesSemantic proximity Read ↗

Structures of Angptl3 and Angptl4, modulators of triglyceride levels and coronary artery diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.